Which Creatinine Test Method is More Accurate for Kidney Function Testing?

Researchers favor the enzymatic method for creatinine detection because of its high specificity and minimal interference. Enzymatic assays function through a multi-step biochemical pathway which contrasts with the Jaffe reaction that depends on a non-specific colorimetric interaction of alkaline picric acid and creatinine together with other chromogens including glucose, proteins or ketones. Creatinine undergoes hydrolysis by creatinine amidohydrolase to form creatine before being further degraded into sarcosine and urea. The enzyme sarcosine oxidase processes sarcosine to produce glycine and hydrogen peroxide (H₂O₂), which subsequently interacts with a chromogen through the Trinder reaction resulting in a detectable color change. The precise nature of this method prevents false positive readings from pseudo-creatinines and hyperbilirubinemia that often distort results from Jaffe-based assessments. Enzymatic approaches demonstrate high concordance with standard IDMS techniques and deliver >95% precision for clinical samples while Jaffe methods show a deviation range of 10–15% in intricate scenarios.

The IDMS method earns gold standard status for creatinine measurement by using isotopic labeling together with advanced mass spectrometry to remove matrix effects and analytical bias. The analytical procedure requires the introduction of a predetermined amount of stable isotope-labeled creatinine (such as ¹³C-creatinine) into the sample to serve as an internal standard. Scientists ionize the mixture before sending it through a mass spectrometer which measures the ratio between natural creatinine and its labeled counterpart. The very similar chemical characteristics of labeled and unlabeled molecules mean that any changes occurring during extraction or ionization impact both samples equally which allows for accurate calibration. IDMS delivers measurement uncertainties below 2% which makes it critical for calibrating routine assays and defining standardized reference intervals. The requirement for costly equipment and expert knowledge restricts this method to reference labs and extensive research projects.

Dry chemistry strips enable quick and portable testing at point-of-care locations with results in 2–5 minutes yet face limitations from poor analytical sensitivity and environmental influences. The strips contain layers with reagents that interact with creatinine present in whole blood or serum to produce a color change which a reflectance meter measures. These devices fail to provide precise detection of minor creatinine level changes (such as early kidney disease) because their coefficients of variation (CVs) surpass 10% relative to laboratory procedures. The kinetics of biochemical reactions can be affected by humidity levels and temperature changes and also hematocrit concentrations resulting in measurement errors. Elevated bilirubin and lipidemia levels might prevent proper color development but hemolysis tends to produce lower than accurate results. Thus, dry chemistry methods are best suited for urgent screenings or resource-limited settings, not for definitive diagnosis or monitoring chronic kidney disease.

Accurate eGFR calculation depends on standardized, interference-resistant creatinine measurements, which directly impact clinical decisions like drug dosing or dialysis eligibility. Enzymatic methods and IDMS are endorsed by guidelines (e.g., KDIGO, NKF) because they address critical flaws in older techniques:

Standardization: IDMS-traceable assays ensure harmonized results across laboratories, reducing inter-lab variability from 20% (Jaffe) to<5%.

Reduced Bias: Enzymatic methods provide accurate creatinine measurements in patients with diabetes or liver disease because Jaffe assays produce false readings from ketones and bilirubin interference.

Early Detection: Enhanced accuracy allows identification of mild renal dysfunction (eGFR 60–90 mL/min/1.73m²) typically undetected by Jaffe-based eGFR calculations.

A patient with an actual creatinine level of 1.2 mg/dL will show 1.0 mg/dL through enzymatic assays resulting in an eGFR of 68 while Jaffe assays show 0.8 mg/dL resulting in an eGFR of 85 which delays CKD staging.

Capillary electrophoresis (CE) and immunosensors represent niche advancements with unique advantages and hurdles:

CE separates creatinine from interferents using an electric field in a silica capillary, achieving high resolution with minimal sample volume (1–10 nL). However, protein adsorption on capillary walls and batch-to-batch reproducibility issues hinder its adoption.

Immunosensors employ anti-creatinine antibodies immobilized on electrodes or optical surfaces. Binding events are transduced into electrical or optical signals, offering ultra-low detection limits (0.01 mg/dL). Yet, cross-reactivity with structurally similar molecules (e.g., creatine) and high production costs remain challenges.

While these technologies are promising for specialized applications (e.g., neonatal testing or multiplexed panels), they currently lack the robustness and cost-effectiveness required to replace enzymatic or IDMS methods in routine practice.